Collaborative partnerships are of increasing importance for successful innovation in the life science industry. The old-fashioned, in-house research of pharmaceutical companies 15 20 years ago, which is no longer tenable, has given way to the current focus on making deals that support the industry’s ailing pipelines and fuel innovation.
In recent years, the biotech and pharmaceutical industries have seen an unprecedented increase in investment. Both large pharma and investors are alert for the next big scheme to expand their portfolios and spur growth. With risk being high, a key part of mitigating this is effective due diligence. Simply put, due diligence is the investigation of a business or asset prior to signing a contract.
Please click here to read the full article by Sanjay Kumar, published in The Financial Express.
